AnalystBook Research · Company Intelligence

Corteva, Inc.

CTVANYSE

Built from Corteva, Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Corteva grew revenue +2.9%, net income +20.6%, and FCF +81.8% ahead of a planned split.

The read at a glance✓ Audited against SEC data
  • GrowthRevenue +2.9% to $17.40BOK
  • ProfitabilityNet income +20.6% to $1.09BOK
  • Cash qualityFCF +81.8% to $2.81BOK
  • MarginsGross +365 bps; FCF +702 bpsOK
  • Balance sheetDebt -13.7% to $1.69BOK
  • Insiders0 buys / 2 sellsWatch

Business

Corteva is a global agriculture company focused on seed and crop protection. It develops commercial seed, traits, crop protection products, biologicals, and digital tools for farmers in about 110 countries.

Where the revenue comes from

Fiscal 2025, as Corteva, Inc. reports it. History and quarterly detail are in the app.

  • Seed$9.9B
  • Crop Protection$7.5B

Leadership changes

From Corteva, Inc.'s own filings, the day they're filed.

  • Judd O'Connor · appointmenteff. 2024-12-01
  • Crop Protection · Chief Commercial Officer · appointment
  • Brook Cunningham · President · appointment

Latest filings

  • 8-K · Company announcement2026-08-31
  • 8-K · Company announcement2026-08-20
  • 8-K · Company announcement2026-08-20
  • 8-K · Company announcement2026-08-14
  • 8-K · Company announcement2026-08-06
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Corteva, Inc., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.